Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability and safety of SHR-8068 in combination with adebrelimab in
subjects with advanced NSCLC To evaluate the efficacy of SHR-8068 in combination with
adebrelimab and platinum-based chemotherapy in subjects with advanced NSCLC